Corcept Therapeutics Incorporated
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.25 billion
- Book Value:
- Revenue TTM:
- $401.86 million
- Operating Margin TTM:
- Gross Profit TTM:
- $396.47 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Corcept Therapeutics Incorporated had its IPO on 2004-04-14 under the ticker symbol CORT.
The company operates in the Healthcare sector and Biotechnology industry. Corcept Therapeutics Incorporated has a staff strength of 299 employees.
Shares of Corcept Therapeutics Incorporated opened at $20.86 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $20.54 - $20.98, and closed at $20.64.
This is a -1.05% slip from the previous day's closing price.
A total volume of 1,622,200 shares were traded at the close of the day’s session.
In the last one week, shares of Corcept Therapeutics Incorporated have slipped by -2.37%.
Corcept Therapeutics Incorporated's Key Ratios
Corcept Therapeutics Incorporated has a market cap of $2.25 billion, indicating a price to book ratio of 4.8621 and a price to sales ratio of 5.4634.
In the last 12-months Corcept Therapeutics Incorporated’s revenue was $401.86 million with a gross profit of $396.47 million and an EBITDA of $113.42 million. The EBITDA ratio measures Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Corcept Therapeutics Incorporated’s operating margin was 28.03% while its return on assets stood at 13.98% with a return of equity of 23.11%.
In Q4, Corcept Therapeutics Incorporated’s quarterly earnings growth was a negative -46.2% while revenue growth was a positive 4.3%.
Corcept Therapeutics Incorporated’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.85 per share while it has a forward price to earnings multiple of 19.4553 and a PEG multiple of 0.61. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Corcept Therapeutics Incorporated’s profitability.
Corcept Therapeutics Incorporated stock is trading at a EV to sales ratio of 4.796 and a EV to EBITDA ratio of 14.6898. Its price to sales ratio in the trailing 12-months stood at 5.4634.
Corcept Therapeutics Incorporated stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $583.43 million
- Total Liabilities
- $72.49 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Corcept Therapeutics Incorporated ended 2023 with $583.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $583.43 million while shareholder equity stood at $501.84 million.
Corcept Therapeutics Incorporated ended 2023 with $0 in deferred long-term liabilities, $72.49 million in other current liabilities, 131000.00 in common stock, $296.39 million in retained earnings and $0 in goodwill. Its cash balance stood at $66.33 million and cash and short-term investments were $431.67 million. The company’s total short-term debt was $1,143,000 while long-term debt stood at $0.
Corcept Therapeutics Incorporated’s total current assets stands at $499.25 million while long-term investments were $4.95 million and short-term investments were $365.34 million. Its net receivables were $31.06 million compared to accounts payable of $11.98 million and inventory worth $6.10 million.
In 2023, Corcept Therapeutics Incorporated's operating cash flow was $0 while its capital expenditure stood at $31000.
Comparatively, Corcept Therapeutics Incorporated paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Corcept Therapeutics Incorporated stock is currently trading at $20.64 per share. It touched a 52-week high of $30.14 and a 52-week low of $30.14. Analysts tracking the stock have a 12-month average target price of $30.8.
Its 50-day moving average was $22.09 and 200-day moving average was $24.5 The short ratio stood at 23.69 indicating a short percent outstanding of 0%.
Around 1096.1% of the company’s stock are held by insiders while 7842.3% are held by institutions.
Frequently Asked Questions About Corcept Therapeutics Incorporated
Similar Industry Stocks (Biotechnology)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.